Cynata Therapeutics
- Short interest
- 0.00%
- −0.62 pp 30d
- as of 13 May 2026
- Reported shorts
- 3.1K
- Shares on issue
- 243.454M
Cynata Therapeutics (CYP) financials
Results, ratios and statements
Latest result
Year to 30 Jun 2026 (FY26) vs FY25, figures in AUD, the reporting currency · Company filing, 31 Aug 2026
- Revenue
- $79.5KM (source: ASX (Markit))vs $227.7KM (source: ASX (Markit)) (FY25)
- ASX (Markit), as at 14 Oct 2026
- NPAT
- −$9.2MM (source: ASX (Markit))vs −$9.4M (FY25)
- ASX (Markit), as at 14 Oct 2026
- EPS (diluted)
- −$0.038F (source: Company filing (extracted))vs −$0.046 (FY25)
- Company filing (extracted), as at 14 Oct 2026
- Rev YoY
- −65.1%FY
- EPS YoY
- n/aFYF (source: Company filing (extracted))
- ASX (Markit)
- Company filing (extracted)
Summary of Annual Report, 28 Sep 2026
Cynata Therapeutics reported no revenue or net profit in its FY2026 annual report, as the company is a pre-revenue biotech. No dividend was declared. The company announced a comprehensive restructuring after two clinical trials failed to meet endpoints, making all employee positions redundant and reducing the board, with a pro forma cash position of ~$1.5 million expected to fund operations beyond FY2027.
Automated summary of the filing; the filing itself is the record.
Key ratios
Year to 30 Jun 2026 (FY); no balance sheet aligned with this period; prices to 14 Oct 2026
- Gross margin
- n/a
- Operating margin
- n/a
- Net margin
- −11,635.2%
- FCF margin
- n/a
- ROE
- n/a
- ROA
- n/a
- FCF conversion
- n/a
- Net debt (excl. leases)
- n/a
- Net debt / EBITDA
- n/a
- Current ratio
- n/a
- Interest cover
- n/a
- Cash dividends paid / net profit
- n/a
- Market cap
- n/a (no share count we can vouch for)
- P/E
- n/a
- P/B
- n/a (no share count we can vouch for)
Ratios use the reporting currency (AUD); market cap is in AUD. Source: ASX (Markit), as at 14 Oct 2026.
Financial statements
Figures in AUD, the reporting currency; Yahoo Finance unless marked
| Line item | FY26 | FY25 | FY24 | FY23 |
|---|---|---|---|---|
| Revenue | $79.5KM (source: ASX (Markit)) | $227.7KM (source: ASX (Markit)) | $417.7KM (source: ASX (Markit)) | $352.9KM (source: ASX (Markit)) |
| Operating income | n/a | −$11.5M | −$12.5M | −$16.5M |
| EBITDA | n/a | −$11.2M | −$12.3M | −$16.3M |
| EBIT | n/a | −$11.5M | −$12.5M | −$16.5M |
| Pretax income | n/a | −$9.4M | −$9.7M | −$14.3M |
| Tax | n/a | $0 | $0 | $0 |
| NPAT | −$9.2MM (source: ASX (Markit)) | −$9.4M | −$9.7M | −$14.3M |
| Net interest income | n/a | $227.7K | $417.7K | $352.9K |
| EPS basic | −$0.038F (source: Company filing (extracted)) | −$0.046 | −$0.054 | −$0.098 |
| EPS diluted | −$0.038F (source: Company filing (extracted)) | −$0.046 | −$0.054 | −$0.098 |
| Shares | n/a | 226.0M | 179.6M | 179.6M |
- ASX (Markit)
- Company filing (extracted)
Financial reports
The company's own filings, newest first
- Annual ReportAnnual Report28 Sep 2026via asx_announcements
- Appendix 4E & Preliminary Final ReportAnnual Results31 Aug 2026via asx_announcements
Figures above come from this filing
- June 2026 Quarterly Activity Report & Appendix 4CQuarterly Report30 Jul 2026via asx_announcements
- March 2026 Quarterly Activity Report & Appendix 4CQuarterly Report30 Apr 2026via asx_announcements
- Appendix 4D & Half-Year Financial StatementsHalf Year Results26 Feb 2026via asx_announcements
- December 2025 Quarterly Activity Report and Appendix 4CQuarterly Report29 Jan 2026via asx_announcements
- September 2025 Quarterly Activity Report and Appendix 4CQuarterly Report31 Oct 2025via asx_announcements
- Annual Report to ShareholdersAnnual Report10 Oct 2025via asx_announcements
- Appendix 4E & Annual ReportAnnual Results28 Aug 2025via asx_announcements
- June 2025 Quarterly Activity Report and Appendix 4CQuarterly Report30 Jul 2025via asx_announcements
Showing 10 of 20 reports